Stockscreener 앱 받기
26.47
2.28%
0.59
시장 영업 전:
26.95
0.48
+1.81%
Pacira Biosciences Inc 주식(PCRX)의 최신 뉴스
Pacira (PCRX) Advances Gene Therapy Manufacturing for Osteoarthritis - GuruFocus
Pacira BioSciences Enrolls First Patient in Mid-stage Trial After Manufacturing Milestone - marketscreener.com
Pacira BioSciences Advances PCRX-201 Development Program with Successful Transition to Scalable Commercial Manufacturing Process - The Manila Times
Pacira's knee gene therapy gets new-process drug for Phase 2 - Stock Titan
Pacira Biosciences Inc (PCRX) Balance Sheet - TradingKey
Pacira Biosciences Inc (PCRX) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Pacira Biosciences Inc (PCRX) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Pacira Biosciences Inc (PCRX) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Pacira Biosciences, Inc. Revenue Breakdown – FWB:82P - TradingView
Faruqi & Faruqi Reminds Pacira BioSciences Investors of the Pendi - The National Law Review
Pacira Biosciences Inc (PCRX) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PCRX|Pacira Biosciences Inc|Price:26.470|Chg%:+0.590 - TradingKey
Pacira BioSciences, Inc. (PCRX) stock price, news, quote and history - Yahoo Finance Singapore
Pacira Pharmaceuticals, Inc. (PCRX) stock price, news, quote and history - Yahoo Finance UK
Pacira stock trades steady as EXPAREL revenue supports margins - Ad-hoc-news.de
Pacira BioSciences (PCRX) Climbs Nearly 2% as Stock Approaches Key Resistance LevelRSI Oversold Picks - dars.gov.et
Pacira Biosciences Inc (PCRX) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Pacira stock trades steady as investors weigh Exparel growth and margin trends - Ad-hoc-news.de
Pacira to Report Second Quarter 2026 Financial Results on Tuesday August 4, 2026 - The Manila Times
Pacira will pair Aug. 4 results with a live investor Q&A - Stock Titan
Pacira BioSciences, Inc. (PCRX) Stock Analysis: Exploring A Potential 17% Upside - DirectorsTalk Interviews
Understanding the Setup: (PCRX) and Scalable Risk - Stock Traders Daily
Pacira stock trades steady as investors weigh Q1 2026 revenue and margin trends - Ad-hoc-news.de
Pacira BioSciences stock trades steady as Exparel revenue supports valuation - Ad-hoc-news.de
PCRX6079820 Bond Coupon Profile — Rate & Payments - TradingView
PCRX6079820 Bond Profile — Key Metrics - TradingView
PCRX6079820 Bond Risk Profile - TradingView
Deals tracker: IKS Health acquires TruBridge in $557M deal - Modern Healthcare
Pacira BioSciences stock trades steady as pain-management pipeline stays in focus - AD HOC NEWS
82P Forecast — Price Target — Prediction for 2027 - TradingView
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - markets.businessinsider.com
Pacira uses stock awards to recruit 10 new employees - Stock Titan
Zimmer Biomet acquires rights to medical device for $140 million - Inside INdiana Business
Enterprise value to revenue forward of Pacira Biosciences, Inc. – BX:82P - TradingView
PCRX's Exparel Wins Separate Reimbursement From UnitedHealthcare - TradingView
Pacira to divest iovera business to Zimmer Biomet in up to $140M deal - MSN
UnitedHealthcare adds separate reimbursement for Exparel By Investing.com - Investing.com Australia
Sector Update: Healthcare - Moomoo
Pacira to Divest iovera Business to Zimmer Biomet in Up To $140M Deal - TradingView
Pacira BioSciences to divest its iovera° business to Zimmer Biomet - Medical Buyer
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL - markets.businessinsider.com
Pacira BioSciences' Exparel Now Separately Reimbursed by UnitedHealthcare Across Outpatient Settings - marketscreener.com
PCRX Reiterated by HC Wainwright & Co. -- Price Target Maintained at $38 - GuruFocus
Pacira BioSciences Announces UnitedHealthcare Now Provides Separate Reimbursement for EXPAREL® - The Manila Times
Zimmer Biomet to acquire iovera device from Pacira for $140m - Yahoo Finance
H.C. Wainwright Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $38 - Moomoo
Price to earnings forward of Pacira BioSciences, Inc. – NASDAQ:PCRX - TradingView
Pacira BioSciences (PCRX) Sells iovera° Business to Zimmer Biome - GuruFocus
Zimmer Biomet Holdings, Inc. agreed to acquire iovera ° Business of Pacira BioSciences from Pacira BioSciences, Inc. for $140 million. - marketscreener.com
Needham Maintains Pacira BioSciences(PCRX.US) With Buy Rating, Maintains Target Price $32 - Moomoo
Pacira Biosciences Announces Agreement to Div - Moomoo
Zimmer to buy Pacira pain relief device for up to $140M - MedTech Dive
Pacira divests iovera device to Zimmer Biomet for up to $140m - Investing.com
Pacira Biosciences Announces Agreement To Divest Its Iovera° Business To Zimmer Biomet - TradingView
Pacira BioSciences stock rises on Zimmer Biomet deal By Investing.com - Investing.com South Africa
Pacira BioSciences stock rises on Zimmer Biomet deal - Investing.com UK
Pacira BioSciences Divests CryoTech to Zimmer Biomet - TipRanks
Pacira BioSciences Announces Agreement to Divest its iovera° Business to Zimmer Biomet - The Manila Times
0.30%
2.01%
자본화:
|
볼륨(24시간):